Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Syndax Pharma (SNDX)

Syndax Pharma (SNDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,115,629
  • Shares Outstanding, K 85,358
  • Annual Sales, $ 0 K
  • Annual Income, $ -209,360 K
  • EBIT $ -321 M
  • EBITDA $ -336 M
  • 60-Month Beta 0.86
  • Price/Sales 67.08
  • Price/Cash Flow N/A
  • Price/Book 3.09

Options Overview Details

View History
  • Implied Volatility 64.85% ( -15.51%)
  • Historical Volatility 94.33%
  • IV Percentile 54%
  • IV Rank 38.74%
  • IV High 127.69% on 03/11/24
  • IV Low 25.12% on 06/04/24
  • Put/Call Vol Ratio 4.27
  • Today's Volume 79
  • Volume Avg (30-Day) 676
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 31,284
  • Open Int (30-Day) 33,515

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.24
  • Number of Estimates 7
  • High Estimate 3.88
  • Low Estimate -1.27
  • Prior Year -1.00
  • Growth Rate Est. (year over year) +124.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.75 +2.51%
on 12/20/24
17.50 -25.31%
on 11/25/24
-3.02 (-18.77%)
since 11/22/24
3-Month
12.75 +2.51%
on 12/20/24
22.50 -41.91%
on 11/11/24
-5.21 (-28.50%)
since 09/24/24
52-Week
12.75 +2.51%
on 12/20/24
25.34 -48.42%
on 02/28/24
-7.87 (-37.58%)
since 12/22/23

Most Recent Stories

More News
Biotech Companies’ Q3 Updates: Promising Cancer Treatments on the Horizon

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As many biotech companies within the oncology space begin to roll...

ONCY : 0.9700 (+7.09%)
IOVA : 7.49 (+0.40%)
SNDX : 13.07 (-1.80%)
ONC.TO : 1.41 (+9.30%)
IBRX : 2.63 (-1.50%)
SWTX : 36.81 (-1.50%)
Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon

/CNW/ -- USA News Group News Commentary – As many biotech companies within the oncology space begin to roll out their end-of-quarter results, the American...

ONCY : 0.9700 (+7.09%)
IOVA : 7.49 (+0.40%)
SNDX : 13.07 (-1.80%)
ONC.TO : 1.41 (+9.30%)
IBRX : 2.63 (-1.50%)
SWTX : 36.81 (-1.50%)
Syndax: Q3 Earnings Snapshot

Syndax: Q3 Earnings Snapshot

SNDX : 13.07 (-1.80%)
Syndax: Q2 Earnings Snapshot

Syndax: Q2 Earnings Snapshot

SNDX : 13.07 (-1.80%)
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END

SNDX : 13.07 (-1.80%)
ATNM : 1.2200 (-1.61%)
KURA : 8.86 (-0.89%)
BMEA : 4.01 (-0.50%)
JNJ : 145.85 (+0.40%)
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies

SNDX : 13.07 (-1.80%)
ATNM : 1.2200 (-1.61%)
KURA : 8.86 (-0.89%)
BMEA : 4.01 (-0.50%)
JNJ : 145.85 (+0.40%)
Syndax: Q1 Earnings Snapshot

Syndax: Q1 Earnings Snapshot

SNDX : 13.07 (-1.80%)
Syndax: Q4 Earnings Snapshot

Syndax: Q4 Earnings Snapshot

SNDX : 13.07 (-1.80%)
Syndax: Q3 Earnings Snapshot

Syndax: Q3 Earnings Snapshot

SNDX : 13.07 (-1.80%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

SNDX : 13.07 (-1.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253...

See More

Key Turning Points

3rd Resistance Point 13.70
2nd Resistance Point 13.51
1st Resistance Point 13.29
Last Price 13.07
1st Support Level 12.88
2nd Support Level 12.69
3rd Support Level 12.47

See More

52-Week High 25.34
Fibonacci 61.8% 20.53
Fibonacci 50% 19.05
Fibonacci 38.2% 17.56
Last Price 13.07
52-Week Low 12.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar